X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Dishman Pharma with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ACTAVIS (US) - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DISHMAN PHARMA   ACTAVIS
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ACTAVIS
Dec-14
DISHMAN PHARMA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs37418,752-   
Low Rs12911,438-   
Sales per share (Unadj.) Rs197.83,376.8-  
Earnings per share (Unadj.) Rs21.2-421.4-  
Cash flow per share (Unadj.) Rs34.7309.8-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.97,324.1-  
Shares outstanding (eoy) m80.69265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.5 28.5%   
Avg P/E ratio x11.9-35.8 -33.1%  
P/CF ratio (eoy) x7.248.7 14.9%  
Price / Book Value ratio x1.42.1 67.9%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,3064,013,841 0.5%   
No. of employees `0000.821.6 3.8%   
Total wages/salary Rs m5,3550-   
Avg. sales/employee Rs Th19,252.741,568.6 46.3%   
Avg. wages/employee Rs Th6,459.50-   
Avg. net profit/employee Rs Th2,064.1-5,187.3 -39.8%   
INCOME DATA
Net Sales Rs m15,961897,882 1.8%  
Other income Rs m265-2,241 -11.8%   
Total revenues Rs m16,226895,641 1.8%   
Gross profit Rs m4,103115,346 3.6%  
Depreciation Rs m1,091194,424 0.6%   
Interest Rs m94428,321 3.3%   
Profit before tax Rs m2,334-109,640 -2.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0-8,043 0.0%   
Tax Rs m624-5,637 -11.1%   
Profit after tax Rs m1,711-112,046 -1.5%  
Gross profit margin %25.712.8 200.1%  
Effective tax rate %26.75.1 519.8%   
Net profit margin %10.7-12.5 -85.9%  
BALANCE SHEET DATA
Current assets Rs m11,018473,069 2.3%   
Current liabilities Rs m9,517345,006 2.8%   
Net working cap to sales %9.414.3 65.9%  
Current ratio x1.21.4 84.4%  
Inventory Days Days11058 190.5%  
Debtors Days Days3566 52.6%  
Net fixed assets Rs m16,304109,640 14.9%   
Share capital Rs m1610-   
"Free" reserves Rs m12,9070-   
Net worth Rs m14,5161,947,473 0.7%   
Long term debt Rs m4,1891,020,514 0.4%   
Total assets Rs m29,8053,569,077 0.8%  
Interest coverage x3.5-2.9 -120.9%   
Debt to equity ratio x0.30.5 55.1%  
Sales to assets ratio x0.50.3 212.9%   
Return on assets %8.9-2.3 -379.8%  
Return on equity %11.8-5.8 -204.9%  
Return on capital %17.5-3.0 -582.2%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Net fx Rs m4,2550-   
CASH FLOW
From Operations Rs m2,786154,184 1.8%  
From Investments Rs m-1,529-369,175 0.4%  
From Financial Activity Rs m-941207,423 -0.5%  
Net Cashflow Rs m316-7,568 -4.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 68.74 Rs / USD

Compare DISHMAN PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare DISHMAN PHARMA With: DR. REDDYS LAB  LUPIN LTD  GLENMARK PHARMA  PANACEA BIOTECH  SUVEN LIFE  



Today's Market

Sensex Ends Day in Green; IT Stocks Lead Gains(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day in above the dotted line.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Sintex's Auditor Resigns. How You Can Protect Yourself from Such Stocks(The 5 Minute Wrapup)

Jul 20, 2018

While the attack on the bad corporate governance is an overhang in the near term...this can be a game-changer in the years to come.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)

Jul 11, 2018

The price signals that MSP sends out, creates its own set of problems.

ICICI Pru Mutual Fund Tarakki Karega! - The Unethical Way?(Outside View)

Jul 11, 2018

PersonalFN explains how ICICI Prudential Mutual Fund flouted the norms of related party transactions while subscribing to the IPO of ICICI Securities.

PPF v/s Mutual Funds: Which Is Better?(Outside View)

Jul 10, 2018

PersonalFN highlights the key points of distinction between PPF and mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS